Skip to main content

Table 1 Patients' characteristics of the three treatment groups analyzed in this follow-up study

From: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

   Treatment group Total p-value
   Antibody18
ch14.18
Oral NB90 maintenance18
chemotherapy
No consolidation   
No. of patients   166 99 69 334  
Age at diagnosis median (years) 3.2 2.9 2.9 3.2 .262
  range (years) 1.0-20.6 1.0-15.0 1.0-11.2 1.0-20.6  
Sex male 95 54 43 192 .602
  female 71 45 26 142  
Protocol NB90 25 99 53 177 <.001
  NB97 141 0 16 157  
ASCT no 63 99 27 189 <.001
  yes 103 0 42 145  
MYCN status Normal 124 56 34 214 .358
  Amplified 38 15 16 69  
  Not known 4 28 19 51  
Disease status after initial treatment CR/VGPR 134 81 52 267 .567
  PR 27 17 16 60  
  MR/SD 5 1 1 7  
\